Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tarsus Pharmaceuticals highlighted continued commercial momentum for XDEMVY, its lead product for Demodex blepharitis, alongside a pipeline with two Phase II assets. Management characterized the company as at an inflection point, implying growth runway remains ahead as investors gain more visibility into the pipeline over the next year. The discussion was largely constructive but contained no new financial guidance or quantitative updates.

Analysis

XDEMVY is moving from a clinical-story multiple into a commercial-execution multiple, which matters because the market usually underestimates how fast an eye-care category can become self-reinforcing once prescribers build habit and reimbursement friction fades. The second-order effect is not just revenue growth, but lower customer acquisition cost per script over time as the brand becomes the default answer for a highly specific, underdiagnosed condition. That creates a pathway for operating leverage to inflect faster than topline, which is what can re-rate a launch-stage biotech into a durable specialty pharma compounder.

The key risk is that early launch strength can mask how narrow the funnel really is: if diagnosis rates stall, refill dynamics disappoint, or physician adoption stays concentrated in a few high-prescribing pockets, the growth curve can decelerate sharply after the initial commercial burst. That makes the next 1-2 quarters more important than the next 1-2 years, because investors will be watching for whether scripts are being pulled forward versus truly expanded. Any reimbursement disruption, competitor launch, or evidence of limited repeat utilization would hit sentiment disproportionately given how much of the equity story is currently anchored to XDEMVY.

The pipeline matters mainly as an option on de-risking the multiple, not near-term earnings. If one of the phase II assets shows a broader ocular-inflammation platform effect, the stock can shift from a one-product launch vehicle to a multi-asset specialty franchise, which would expand the valuation range materially. Conversely, if pipeline progress is slow, the equity will trade much more like a commercial momentum name and lose some of the scarcity premium investors are currently willing to pay.

The contrarian angle is that consensus may be too focused on the launch slope and not focused enough on durability of demand. In specialty eye disease, the biggest upside often comes from persistence and new physician conversion, but the biggest disappointment comes when the easy patients are treated first and the remaining addressable population is harder to identify. That makes the setup attractive, but only if the company can keep proving breadth of prescriber adoption rather than just early enthusiasm.

Key Decisions for Investors

• Long TARS into the next quarterly update, with a 3-6 month horizon; upside comes from multiple expansion if script growth and operating leverage both continue, but size modestly because launch names can reprice violently on any slowdown.
• Buy TARS call spreads 3-6 months out to express asymmetric upside from continued XDEMVY momentum; structure for a 2:1 to 3:1 reward/risk profile since the market is likely underpricing sustained commercial cadence.
• If already long, trim only on evidence of funnel saturation rather than headline volatility; use a trailing stop tied to prescription trend inflection, not day-to-day price action.
• Pair long TARS vs short a slower-growth ophthalmology peer basket if available, betting that launch execution and near-term revisions will outweigh broader sector beta over the next 1-2 quarters.
• Watch for any evidence of payer friction or persistence decay; if those metrics weaken, reduce exposure quickly because the stock’s rerating thesis depends on durability, not just initial uptake.